O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression

Glycobiology

Volumn 26, Issue 8, 2016, Pages 820-833

  Zhu, Guizhou ^a   Tao, Tao ^a   Zhang, Dongmei ^a   Liu, Xiaojuan ^a   Qiu, Huiyuan ^a   Han, Lijian ^a   Xu, Zhiwei ^a   Xiao, Ying ^a   Cheng, Chun ^a   Shen, Aiguo ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

cell proliferation; hepatocellular carcinoma; histone deacetylase 1; O GlcNAc transferase; O GlcNAcylation

Indexed keywords

HISTONE DEACETYLASE 1; N ACETYLGLUCOSAMINE; O LINKED N ACETYLGLUCOSAMINE; PROTEIN P21; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HDAC1 PROTEIN, HUMAN; HISTONE; N ACETYLGLUCOSAMINYLTRANSFERASE; O-GLCNAC TRANSFERASE;

ACYLATION; ARTICLE; CANCER GROWTH; CASE REPORT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME; ENZYME ACTIVATION; ENZYME INHIBITION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; UPREGULATION; CELL MOTION; DISEASE EXACERBATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; PATHOLOGY; PROTEIN PROCESSING;

ACYLATION; CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEP G2 CELLS; HISTONE DEACETYLASE 1; HISTONES; HUMANS; LIVER NEOPLASMS; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84988527756     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cww025     Document Type: Article

References (54)

1. Brunmeir R, Lagger S, Seiser C. 2009. Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation. Int J Dev Biol. 53:275-289.
2. Campisi J. 2000. Cancer, aging and cellular senescence. In Vivo. 14:183-188.
3. Chen Q, Chen Y, Bian C, Fujiki R, Yu X. 2013. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature. 493:561-564.
4. Chesire DR, Isaacs WB. 2003. Beta-catenin signaling in prostate cancer: An early perspective. Endocr Relat Cancer. 10:537-560.
5. Comer FI, Hart GW. 2000. O-Glycosylation of nuclear and cytosolic proteins. Dynamic interplay between O-GlcNAc and O-phosphate. J Biol Chem. 275:29179-29182.
6. Dennis JW, Nabi IR, Demetriou M. 2009. Metabolism, cell surface organization, and disease. Cell. 139:1229-1241.
7. Fausto N, Campbell JS, Riehle KJ. 2006. Liver regeneration. Hepatology. 43: S45-S53.
8. Fujiki R, HashibaW, Sekine H, Yokoyama A, Chikanishi T, Ito S, Imai Y, Kim J, He HH, Igarashi K, et al. 2011. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature. 480:557-560.
9. Gambetta MC, Oktaba K, Muller J. 2009. Essential role of the glycosyltransferase sxc/Ogt in polycomb repression. Science. 325:93-96.
10. Gartel AL, Najmabadi F, Goufman E, Tyner AL. 2000. A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription. Oncogene. 19:961-964.
11. Glozak MA, Seto E. 2007. Histone deacetylases and cancer. Oncogene. 26:5420-5432.
12. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. 2004. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoterassociated proteins, including HDAC1. Proc Natl Acad Sci USA. 101:1241-1246.
13. Gupta GP, Massague J. 2006. Cancer metastasis: Building a framework. Cell. 127:679-695.
14. Harbour JW, Dean DC. 2000. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol. 2:E65-E67.
15. Hart GW, Housley MP, Slawson C. 2007. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 446:1017-1022.
16. HartGW, Slawson C, Ramirez-Correa G, Lagerlof O. 2011. Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 80:825-858.
17. Hochberg Z. 2010. Hormone resistance at the clinical level. Sci Signal. 3:pt1.
18. Huang L, Sowa Y, Sakai T, Pardee AB. 2000. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene. 19:5712-5719.
19. Iakova P, Timchenko L, Timchenko NA. 2011. Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol. 21:28-34.
20. Kim NH, Kim SN, Kim YK. 2011. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion. Biochem Biophys Res Commun. 404:915-921.
21. Kruh J. 1982. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem. 42:65-82.
22. Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, et al. 2003. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol. 23:2669-2679.
23. Lee JS, Smith E, Shilatifard A. 2010. The language of histone crosstalk. Cell. 142:682-685.
24. Mariadason JM. 2008. HDACs and HDAC inhibitors in colon cancer. Epigenetics. 3:28-37.
25. Marshall S, Bacote V, Traxinger RR. 1991. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 266:4706-4712.
26. Marshall S, Duong T,Wu T, Hering MA, Yada J, Higgins S, Orbus RJ, Yan ZH, Rumberger JM. 2003. Enhanced expression of uridine diphosphate-N-acetylglucosaminyl transferase (OGT) in a stable, tetracycline-inducible HeLa cell line using histone deacetylase inhibitors: Kinetics of cytosolic OGT accumulation and nuclear translocation. Anal Biochem. 319: 304-313.
27. Niyazi M, Niyazi I, Belka C. 2007. Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol. 2:4.
28. Peinado H, Ballestar E, Esteller M, Cano A. 2004. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/ HDAC2 complex. Mol Cell Biol. 24:306-319.
29. Pflum MK, Tong JK, Lane WS, Schreiber SL. 2001. Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J Biol Chem. 276:47733-47741.
30. Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D, et al. 2011. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 459:129-139.
31. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y. 2007. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 72:69-74.
32. Rundlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM, Grunstein M. 1996. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci USA. 93:14503-14508.
33. Sakabe K, Wang Z, Hart GW. 2010. Beta-N-acetylglucosamine (O-GlcNAc) is part of the histone code. Proc Natl Acad Sci USA. 107:19915-19920.
34. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, et al. 2007. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol. 27:4784-4795.
35. Shi-Chen Ou D, Lee SB, Chu CS, Chang LH, Chung BC, Juan LJ. 2011. Transcriptional activation of endoplasmic reticulum chaperone GRP78 by HCMV IE1-72 protein. Cell Res. 21:642-653.
36. Slawson C, Hart GW. 2011. O-GlcNAc signalling: Implications for cancer cell biology. Nat Rev Cancer. 11:678-684.
37. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. 1997. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun. 241:142-150.
38. Su K, Yang X, Roos MD, Paterson AJ, Kudlow JE. 2000. Human Sug1/p45 is involved in the proteasome-dependent degradation of Sp1. Biochem J. 348(Pt 2):281-289.
39. Tian SY, Chen SH, Shao BF, Cai HY, Zhou Y, Zhou YL, Xu AB. 2014. Expression of leucine aminopeptidase 3 (LAP3) correlates with prognosis and malignant development of human hepatocellular carcinoma (HCC). Int J Clin Exp Pathol. 7:3752-3762.
40. Wang F, Sloss C, Zhang X, Lee SW, Cusack JC. 2007. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res. 67:8486-8493.
41. Wang GL, Salisbury E, Shi X, Timchenko L, Medrano EE, Timchenko NA. 2008. HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta. J Biol Chem. 283:26179-26187.
42. Wang Z, Gucek M, Hart GW. 2008. Cross-talk between GlcNAcylation and phosphorylation: Site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc Natl Acad Sci USA. 105:13793-13798.
43. Wang Z, Pandey A, Hart GW. 2007. Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Mol Cell Proteomics. 6:1365-1379.
44. Whetstine JR, Ceron J, Ladd B, Dufourcq P, Reinke V, Shi Y. 2005. Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase. Mol Cell. 18:483-490.
45. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, DePinho RA, Dannenberg JH. 2010. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 29:2586-2597.
46. Witt O, Deubzer HE, Milde T, Oehme I. 2009. HDAC family: What are the cancer relevant targets? Cancer Lett. 277:8-21.
47. Wu J, Du C, Lv Z, Ding C, Cheng J, Xie H, Zhou L, Zheng S. 2013. The upregulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig Dis Sci. 58:3545-3553.
48. Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H, et al. 2012. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS ONE. 7:e34265.
49. Yang JD, Roberts LR. 2010. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448-458.
50. Yang X, Zhang F, Kudlow JE. 2002. Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: Coupling protein O-GlcNAcylation to transcriptional repression. Cell. 110:69-80.
51. Zachara NE, Hart GW. 2006. Cell signaling, the essential role of O-GlcNAc! Biochim Biophys Acta. 1761:599-617.
52. Zeidan Q, Hart GW. 2010. The intersections between O-GlcNAcylation and phosphorylation: Implications for multiple signaling pathways. J Cell Sci. 123:13-22.
53. Zhu Q, Zhou L, Yang Z, Lai M, Xie H, Wu L, Xing C, Zhang F, Zheng S. 2012. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol. 29:985-993.
54. Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G, Lagger S, et al. 2010. The cyclindependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol. 30:1171-1181.